Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1983 Jul;79(3):725–729. doi: 10.1111/j.1476-5381.1983.tb10010.x

Interactions of gamma-aminobutyric acid and noradrenaline in the high pressure neurological syndrome.

A Angel, M J Halsey, B Wardley-Smith
PMCID: PMC2044897  PMID: 6652352

Abstract

The effects on the high pressure neurological syndrome (HPNS) of reducing brain noradrenaline (NA) levels were studied in adult rats. The onset of tremors and convulsions, which occur as pressure is increased, were used as endpoints for assessing the onset and severity of the HPNS. Neonatal treatment with 6-hydroxydopamine (6-OHDA; 100 mg kg-1 i.p. alternate days from birth for 2 weeks) which depleted brain NA, produced no change in the HPNS as assessed by the appearance of tremors and convulsions. A second series of NA-depleted rats and equivalent controls were treated with a GABA agonist, muscimol, 0.1 microgram intracerebroventricularly. Subsequently the rats were exposed to pressure and the onset and severity of the HPNS was assessed by observation of tremors and convulsions. A combination of NA depletion and intracerebroventricular injection of muscimol significantly raised the onset pressures for tremors and convulsions, i.e. delayed the appearance of the HPNS. These results are consistent with the HPNS being associated with a disturbance in the balance of two or more neurotransmitter systems, rather than simply an increase or reduction in levels of a single transmitter.

Full text

PDF
725

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bichard A. R., Little H. J. Drugs that increase gamma-aminobutyric acid transmission protect against the high pressure neurological syndrome. Br J Pharmacol. 1982 Jul;76(3):447–452. doi: 10.1111/j.1476-5381.1982.tb09238.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brauer R. W., Beaver R. W., Hogue C. D., 3rd, Ford B., Goldman S. M., Venters R. T. Intra- and interspecies variability of vertebrate high-pressure neurological syndrome. J Appl Physiol. 1974 Dec;37(6):844–851. doi: 10.1152/jappl.1974.37.6.844. [DOI] [PubMed] [Google Scholar]
  3. Brauer R. W., Beaver R. W., Lahser S., Mansfield W. M., Sheehan M. E. Time, rate, and temperature factors in the onset of high-pressure convulsions. J Appl Physiol Respir Environ Exerc Physiol. 1977 Aug;43(2):173–182. doi: 10.1152/jappl.1977.43.2.173. [DOI] [PubMed] [Google Scholar]
  4. Brauer R. W., Goldman S. M., Beaver R. W., Sheehan M. E. N2, H2, and N2O antagonism of high pressure neurological syndrome in mice. Undersea Biomed Res. 1974 Mar;1(1):59–72. [PubMed] [Google Scholar]
  5. Chapman A. G., Riley K., Evans M. C., Meldrum B. S. Acute effects of sodium valproate and gamma-vinyl GABA on regional amino acid metabolism in the rat brain: incorporation of 2-[14C]glucose into amino acids. Neurochem Res. 1982 Sep;7(9):1089–1105. doi: 10.1007/BF00964888. [DOI] [PubMed] [Google Scholar]
  6. Clark D. W., Laverty R., Phelan E. L. Long-lasting peripheral and central effects of 6-hydroxydopamine in rats. Br J Pharmacol. 1972 Feb;44(2):233–243. doi: 10.1111/j.1476-5381.1972.tb07259.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fahn S., Côté L. J. Regional distribution of gamma-aminobutyric acid (GABA) in brain of the rhesus monkey. J Neurochem. 1968 Mar;15(3):209–213. doi: 10.1111/j.1471-4159.1968.tb06198.x. [DOI] [PubMed] [Google Scholar]
  8. Green C. J., Halsey M. J., Wardley-Smith B. Possible protection against some of the physiological effects of high pressure [proceedings]. J Physiol. 1977 May;267(1):46P–47P. [PubMed] [Google Scholar]
  9. Hunger W. L., Jr, Bennett P. B. The causes, mechanisms and prevention of the high pressure nervous syndrome. Undersea Biomed Res. 1974 Mar;1(1):1–28. [PubMed] [Google Scholar]
  10. Koblin D. D., Little H. J., Green A. R., Daniels S., Smith E. B., Paton W. D. Brain monoamines and the high pressure neurological syndrome. Neuropharmacology. 1980 Nov;19(11):1031–1038. doi: 10.1016/0028-3908(80)90098-2. [DOI] [PubMed] [Google Scholar]
  11. Lindvall O., Björklund A. The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method. Acta Physiol Scand Suppl. 1974;412:1–48. [PubMed] [Google Scholar]
  12. Rowland-James P., Wilson M. W., Miller K. W. Pharmacological evidence for multiple sites of action of pressure in mice. Undersea Biomed Res. 1981 Mar;8(1):1–11. [PubMed] [Google Scholar]
  13. Shellenberger M. K., Gordon J. H. A rapid, simplified procedure for simultaneous assay of norepinephrine, dopamine, and 5-hydroxytryptamine from discrete brain areas. Anal Biochem. 1971 Feb;39(2):356–372. doi: 10.1016/0003-2697(71)90426-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES